Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06572423 · ClinicalTrials.gov registry record · NA

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

A NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
43
Enrollment target
1
Study location

NCT06572423 is a NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 43 participants, below the 412-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06572423, a NA study of Head and Neck Carcinoma and Metastatic Head and Neck Carcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic head and neck cancer (HNC) who are ineligible for or decline standard of care treatment. Researchers want to evaluate if using HyperArc and PULSAR together will deliver higher, possibly more effective doses, resulting in better tumor control with the same or fewer side effects than smaller routine doses. PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment. HyperArc radiation treatment planning technology is a tool that allows for target dose escalation to tumor tissue while maintaining minimal head and neck organs-at-risk doses compared to other radiation treatment planning software. Undergoing PULSAR and HyperArc technology together may be a safe and effective palliative treatment option for patients with HNC.

Conditions Studied

Head and Neck Carcinoma Metastatic Head and Neck Carcinoma Recurrent Head and Neck Carcinoma Localized Head and Neck Carcinoma

Interventions

  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Positron Emission Tomography
  • PROCEDURE Personalized ultrafractionated stereotactic adaptive radiotherapy
  • RADIATION Volume Modulated Arc Therapy

Study Locations (1)

California

  • University of California at Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2024-10-25
Est. Completion 2029-12-16
Phase NA

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06572423

The ClinicalTrials.gov registry entry for NCT06572423 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT06572423 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06572423 about?

NCT06572423 is a clinical study titled "Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)". This trial tests how well personalized ultra fractionated stereotactic adaptive radiotherapy (PULSAR) works together with HyperArc© radiation treatment planning technology for palliative (holistic pain and symptom control) tumor control in patients with primary or recurrent, localized or metastatic ...

What is the current status of trial NCT06572423?

This trial is currently recruiting. It is a NA study. The enrollment target is 43 participants. The study started on 2024-10-25. Estimated completion is 2029-12-16.

What conditions does trial NCT06572423 study?

This clinical trial studies the following conditions: Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Localized Head and Neck Carcinoma.

What interventions are being tested in trial NCT06572423?

The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Personalized ultrafractionated stereotactic adaptive radiotherapy (PROCEDURE), Volume Modulated Arc Therapy (RADIATION).

Who is sponsoring clinical trial NCT06572423?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06572423 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Carcinoma

All registered trials for this condition

Metastatic Head and Neck Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.